Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: viral haemorrhagic fever therapeutics - Alnylam/USAMRIID

Drug Profile

Research programme: viral haemorrhagic fever therapeutics - Alnylam/USAMRIID

Alternative Names: VP35 siRNA - Alnylam

Latest Information Update: 22 Oct 2013

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Alnylam Pharmaceuticals; United States Army Medical Research Institute of Infectious Diseases
  • Class Small interfering RNA
  • Mechanism of Action RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Viral haemorrhagic fevers

Most Recent Events

  • 22 Oct 2013 Discontinued - Preclinical for Viral haemorrhagic fevers in USA (Parenteral)
  • 31 Dec 2011 No development reported - Preclinical for Viral haemorrhagic fevers in USA (Parenteral)
  • 07 Aug 2008 Alnylam is awarded continued funding of $US7.5 million from the US NIAID to support development of an RNAi therapeutic against viral haemorrhagic fevers (including Ebola)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top